Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 41 to 50 of 118 total matches.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
use effective contraception during treatment with fam-trastuzumab deruxtecan and for at least 7 months ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
women should
generally be avoided
Women who could become
pregnant should use effective
contraception ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
of drugs
metabolized by these isozymes, including oral
contraceptives.
Use of mavacamten ...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
contraception does not qualify for treatment
with the drug.
VULVOVAGINAL CANDIDIASIS — Vulvovaginal ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
with female
partners of reproductive potential should use effective
contraception during treatment ...
The oral kinase inhibitor alpelisib (Vijoice – Novartis)
has been approved by the FDA for treatment of
patients ≥2 years old with severe manifestations of
PIK3CA-related overgrowth spectrum (PROS) who
require systemic treatment. Alpelisib is the first
drug to be approved in the US for this indication.
It was also approved in 2019 as Piqray for use in
combination with fulvestrant for treatment of certain
types of breast cancer.
In Brief: Zanubrutinib (Brukinsa) for CLL or SLL (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
contraceptive method while taking
the drug and for 1 week after the last dose. No data
are available ...
The Bruton's tyrosine kinase (BTK) inhibitor
zanubrutinib (Brukinsa), which was previously
approved by the FDA for treatment of mantle cell
lymphoma, Waldenström's macroglobulinemia,
and relapsed or refractory marginal zone
lymphoma, has now been approved for treatment
of chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL) in adults. The BTK
inhibitors ibrutinib (Imbruvica) and acalabrutinib
(Calquence) were approved earlier for treatment of
CLL and SLL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e33-4 doi:10.58347/tml.2023.1670e | Show Introduction Hide Introduction
In Brief: A Second Indication for Tucatinib (Tukysa) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
at the recommended
dose. Women of reproductive potential and their male
partners should use effective contraception ...
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type human
epidermal growth factor receptor 2 (HER2)-positive
unresectable or metastatic colorectal cancer
that has progressed following treatment with
fluoropyrimidine-, oxaliplatin-, and irinotecan-based
chemotherapy regimens. Tucatinib was approved in
2020 for use in combination with trastuzumab and
capecitabine (Xeloda, and generics) for treatment
of adults with advanced unresectable or...
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e37-8 doi:10.58347/tml.2023.1670g | Show Introduction Hide Introduction
In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
effective contraception during treatment
and for 6 months (females) or 3 months (males) after
the last ...
Sacituzumab govitecan-hziy (Trodelvy – Gilead) has
been approved for treatment of unresectable locally
advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative breast cancer in adults who received
prior endocrine therapy and ≥2 additional systemic
therapies for metastatic disease. It was previously
approved for treatment-refractory metastatic triplenegative
breast cancer and for treatment of locally
advanced or metastatic urothelial cancer in adults
who received platinum-based chemotherapy and a
programmed death receptor-1...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e43-4 doi:10.58347/tml.2023.1671g | Show Introduction Hide Introduction
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
fetal harm and death.
Women of reproductive potential should use effective
contraception during ...
Atezolizumab (Tecentriq – Genentech), an immune
checkpoint inhibitor, has been approved by the FDA
for treatment of unresectable or metastatic alveolar
soft part sarcoma (ASPS) in patients ≥2 years old. It
was previously approved for treatment of non-small
cell lung cancer, small cell lung cancer, hepatocellular
cancer, and melanoma (see Table 1). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder that affects mostly
adolescents and young adults; <1% of soft tissue
sarcomas are ASPS.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e56-7 doi:10.58347/tml.2023.1673d | Show Introduction Hide Introduction
Cemiplimab (Libtayo) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
harm and death.
Women of reproductive potential should use effective
contraception during treatment ...
The FDA has approved cemiplimab-rwlc (Libtayo –
Regeneron), an immune checkpoint inhibitor, for use in
combination with platinum-based chemotherapy for
first-line treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) in adults with no
epidermal growth factor receptor (EGFR), anaplastic
lymphoma kinase (ALK), or ROS1 aberrations and
who are not candidates for surgical resection or
chemoradiation. The drug was previously approved
for first-line treatment of NSCLC in patients whose
tumors have high PD-L1 expression and no genomic
tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8 doi:10.58347/tml.2023.1674e | Show Introduction Hide Introduction